- Platform-Backed Pharma Deals: Absci’s AI-wet lab integration is fueling major collaborations with Merck and AstraZeneca, offering transformative funding potential.
- AI That Builds Antibodies: Absci’s full-stack “design-make-test” system sets it apart in a crowded AI drug discovery field.
- Clinical Milestone Incoming: Human trial data for its lead IBD drug is expected in late 2025, a crucial test of platform credibility.
Absci blends AI and biology—end-to-end
Unlike other AI drug startups that rely on outsourcing, Absci integrates generative AI with in-house lab automation, controlling the full pipeline from molecular design to validation. This makes drug creation faster, cheaper, and more iterative. The platform is now entering the clinic, with its lead program, ABS-101 for inflammatory bowel disease, having started first-in-human dosing.
Big pharma is betting on Absci’s approach
Merck and AstraZeneca have partnered with Absci on deals potentially worth over $850 million, drawn by its ability to design differentiated biologics. AMD’s $20 million investment adds strategic computing power to fuel future growth. These partnerships not only offer non-dilutive capital but also signal growing confidence in AI-led drug pipelines.
Key data could re-rate the story
Interim data from the ABS-101 trial is expected in H2 2025 and will be closely watched as the first clinical validation of Absci’s platform. Its next program, ABS-201, targeting androgenic alopecia, is also set to enter human trials in early 2026. Analyst sentiment remains bullish, with expectations for meaningful upside if trial outcomes are positive.
Strong balance sheet, but high-stakes road ahead
Absci has over $130 million in cash and minimal debt, giving it runway into 2027. However, it remains pre-revenue with high R&D spend and no approved products—so execution on clinical data and partnership milestones will be critical in sustaining long-term investor confidence.
About Absci
Absci Corporation is a biotechnology company using generative AI and automated wet labs to create new antibody therapeutics faster. Its platform powers drug discovery partnerships with global pharma leaders like Merck and AstraZeneca. Learn more at www.absci.com
By
